LIFELOC TECHNOLOGIES (LCTC) Stock Price, News & Analysis

Lifeloc Technologies, Inc. (OTC:LCTC) is a U.S.-based manufacturer focused on the development and production of breath alcohol testing devices and drug detection systems. According to company disclosures and press releases, Lifeloc describes itself as a trusted manufacturer of evidential breath alcohol testers and related training and supplies for workplace, law enforcement, corrections and international customers. The company’s common stock trades over-the-counter under the symbol LCTC, and it is a fully reporting issuer with filings available through the U.S. Securities and Exchange Commission.

Core business and product lines

Lifeloc’s core business centers on portable breath alcohol testers and associated equipment. The company highlights several product families in its public communications:

• L-series LX9 and LT7 breath alcohol testers, which Lifeloc states are designed to meet previously unaddressable market needs such as smart phone pairing, wider temperature use ranges and fast customization that incorporates local languages.
• FC-series evidential breath alcohol devices, which the company notes remain popular with many law enforcement and international organizations.
• Easycal® automated calibration station, described as the only automated calibration available for portable breath alcohol testers, used to support and protect the installed base of Lifeloc instruments and to help drive market share gains, particularly for workplace-focused devices.
• Phoenix® 6.0 BT and EV 30 workplace devices, which Lifeloc associates with workplace alcohol testing applications.

Across its disclosures, Lifeloc emphasizes evidential-grade testing, portability, and the integration of calibration and training support as important aspects of its offering to workplace, law enforcement, corrections and international customers.

SpinDetect™ / SpinDx™ drug detection platform

In addition to alcohol testing, Lifeloc is investing heavily in a next-generation centrifugal drug analyzer platform. In its press releases, the company refers to this technology as SpinDetect™ or as a product based on the licensed SpinDx™ microfluidic technology from Sandia Corporation. Lifeloc describes SpinDetect/SpinDx as a compact, microfluidic, “lab-on-a-disk” system intended for rapid, on-site drug-of-abuse testing.

According to Lifeloc, laboratory testing of the SpinDetect/SpinDx system using human saliva samples has shown the ability to detect:

• delta-9-THC
• cocaine
• fentanyl
• amphetamine
• methamphetamine
• morphine
• MDMA
• benzodiazepines

The company reports that these results have been validated against liquid chromatography-mass spectrometry (LCMS) testing of human samples, with detection limits around 10 ng/ml in its internal testing. Lifeloc describes the SpinDetect/SpinDx platform as using pre-loaded, shelf-stable test disks that perform automated analysis once a sample is introduced, with oral-fluid results displayed in under 15 minutes in demonstration settings.

Target applications and markets

In its public statements, Lifeloc links its products and development programs to several application areas:

• Workplace testing – through Phoenix® 6.0 BT, EV 30 and other workplace-oriented breath alcohol testers.
• Law enforcement and traffic safety – via FC-series evidential devices, L-series instruments, and the planned integration of SpinDetect/SpinDx with the LX9 breathalyzer for potential roadside marijuana breath testing.
• Corrections and international customers – as recurring customer categories for breath alcohol testers and related supplies.
• Drug-of-abuse detection – with SpinDetect/SpinDx intended for use at roadside, in emergency rooms, forensic laboratories and workplace test sites, as described by the company.

Lifeloc also notes that the same microfluidic “lab-on-a-disk” system used in SpinDetect may be adaptable to other biological or chemical targets, such as food or water contaminants, neonatal or veterinary drug residues, or environmental toxins. The company characterizes this as a potential extension of the platform into public health, food safety and environmental testing, while acknowledging that additional research, licensing and regulatory clearances would be required.

Regulatory and reporting status

Lifeloc states that it is a fully reporting company, with SEC filings available to investors. Recent Form 8-K filings reference:

• The release of quarterly operating results.
• Participation in investor conferences.
• An Agreement and Plan of Merger under which a wholly owned subsidiary of Lifeloc is expected to merge with Electronic Systems Technology, Inc., with ELST surviving as a wholly owned subsidiary of Lifeloc, subject to customary closing conditions.

The company’s common stock is registered under the symbol LCTC. Lifeloc has also disclosed that its shares began trading on the OTCID tier of the OTC Markets as of July 1, 2025, replacing its prior OTC Pink Current Market status for fully reporting companies.

Research and development focus

Lifeloc’s financial and narrative disclosures emphasize high research and development spending as a major driver of recent operating losses. The company attributes this primarily to the push to commercialize the SpinDetect/SpinDx centrifugal drug analyzer platform. It has discussed:

• Beta testing of oral-fluid delta-9-THC detection using prototype readers under signed beta-testing agreements.
• Plans for staged product releases, beginning with single-analyte THC disks followed by multi-drug panels.
• Future development paths that may include additional sample types, such as blood and breath, and a combined LX9 breathalyzer plus THC SpinDetect/SpinDx unit as a roadside marijuana breath testing system.

Lifeloc has also disclosed patent activity related to the SpinDx system and investments in research and development equipment, software and space modifications. The company notes that continued progress toward commercialization will depend in part on securing additional financing.

Financing and capital structure developments

Public releases from Lifeloc describe several financing steps taken to support growth and product development:

• A subordinated debenture financing of $750,000 with Diamond Bridge Capital, LP, accompanied by a warrant to purchase shares of common stock, intended to fund SpinDx commercialization and other growth initiatives.
• A line of credit with Citywide Banks, described as a $750,000 facility to support SpinDx development and working capital needs.
• A private placement of common stock at $3.80 per share, raising $798,000 through investment by EDCO Partners, LLLP, which Lifeloc identifies as its largest stockholder.

The company links these financings to its strategy of prioritizing long-term value creation and product development over short-term profitability, particularly for the SpinDetect/SpinDx platform.

Company scale and classification

Based on its SEC filings and over-the-counter listing, Lifeloc is a smaller public company in the manufacturing sector, with an industry classification in analytical laboratory instrument manufacturing. Its financial statements show revenue derived primarily from product sales, along with smaller contributions from royalties and rental income.